This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Japan IP court backs Toray's anti-itching drug patent extension over Sawai challenge

By Toko Sekiguchi ( July 22, 2025, 07:52 GMT | Insight) -- Japan’s Intellectual Property High Court upheld Toray Industries' patent extension for its anti-itch drug Remitch, rejecting Sawai Pharmaceutical’s claim that the extension exceeded legal limits. The court found that the approved salt form was within the patent’s scope and that earlier capsule trial data validly supported the regulatory approval of the orally dissolvable tablets.Japan’s Intellectual Property High Court has upheld Toray Industries’ extended patent rights over its anti-itch drug Remitch, rejecting a challenge from Japan’s leading generics maker Sawai Pharmaceutical that questioned both the eligibility and duration of the extension....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections